Anixa Biosciences, Inc. (ANIX) compared with its closest peers (AARD, EQ, SPRB, HURA, GNLX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $148.57M | -4.5 |
| Equillium, Inc. (EQ) | $145.20M | -4.0 |
| Spruce Biosciences, Inc. (SPRB) | $141.05M | -1.7 |
| TuHURA Biosciences, Inc. (HURA) | $127.13M | -1.2 |
| Genelux Corporation (GNLX) | $122.61M | -5.1 |
| Inovio Pharmaceuticals, Inc. (INO) | $122.01M | -1.0 |
| Neonc Technologies Holdings, Inc. (NTHI) | $121.38M | -2.6 |
| Cumberland Pharmaceuticals Inc. (CPIX) | $114.10M | -20.5 |
| Coya Therapeutics, Inc. (COYA) | $114.01M | -4.6 |
| Rafael Holdings, Inc. (RFL) | $109.89M | -1.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
ANIX overview · ANIX earnings · ANIX financials · ANIX KPIs · ANIX investor relations · ANIX ownership · ANIX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.